Ashley Almanza Chief Executive





Agenda

- Business review
- Interim results
- Capital structure and placing
- Outlook

November: Strategy update



Agenda

- Business review
- Interim results
- Capital structure and placing
- Outlook



Business Review - Initial Assessment

- Strong market positions, especially in higher-growth developing markets
- Material growth opportunities
- Expertise in core businesses of security, cash and outsourcing
- Balance sheet stretched
- Resource and capability gaps exist in key areas
- Strategic focus:
 - Under-investing in some high growth markets/sectors
 - Restructure or exit/dispose in some markets
 - Invested in non-core / non-material businesses
- Capital discipline and portfolio management to be optimised
- Cash flow management not optimised
- Review of operational and organisational efficiency
- Contract and operational risk management needs strengthening



Future management of the business


- Review strategic focus, including portfolio
- Restructure under-performing businesses
- Capital discipline with focus on returns and risk
- Strengthen balance sheet: cash flow, disposals, placing
- Strengthening senior management cadre
- Targeted investment in organisational capacity and capability
- Performance and reward:
 - Quality of sales and earnings; sharp focus on <u>all</u> components of cash flow
- Enhance risk management, including H&S, operations and contract life cycle management
- Balanced assessment of investment opportunities: organic and M&A

Focus on delivering sustainable, profitable growth



Global sales pipeline at 30 June 2013

Annual Contract Value – award expected in next twelve months





Agenda

- Business update
- Interim results
- Capital structure and placing
- Outlook

Figures in the following slides are extracted from the company's unaudited interim results



H1 2013 Results Highlights

- Organic growth of 5.4%; 13% organic growth in developing markets
- PBITA of £201m (2012: £202m). Margin 5.5% (2012: 5.9%)
- Estimated restructuring cost of c£30-35m for UK, Ireland and Europe: 2013/14
- Will continue to look for opportunities to save costs across the group
- Review of group's assets and liabilities resulted in one off charge of £180m
- Cash generated by continuing operations of £218m. Net debt of £1.95 bn
- Underlying EPS of 6.6 pence includes pension interest charge (2012: 7.6p)
- Interim dividend unchanged: 3.42p per share



2012 Profit & Loss reconciliation

£m	June 2012	December 2012
PBITA as reported in 2012	236	516
Discontinued businesses	(16)	(18)
Other adjustments	(20)	(32)
Total underlying 2012 at actual FX	200	466
FX	2	8
Total underlying 2012 at current FX	202	474
Implied margin at actual FX	5.9%	6.7%
Underlying EPS at actual FX	7.5p	17.4p



Review of group's assets and liabilities

- Outcome of review at half year:
 - £132m impairment to PBITA relating to impairment of fixed assets and debtors and recognition of liabilities
 - £48m impairment to balance sheet relating to acquisition goodwill
 - £85m impairment charge to discontinued operations
 - Revised treatment of 'one-off' profits e.g. profits on disposal of businesses and sale and leasebacks



Profit and Loss – Continuing operations

Six months ended 30 June 2013

£m			2013					2012 at cons	stant FX		
	Underlying Results	Acquisition items and discontinued operations	Restructure	Impairment and other items	Total	Underlying Results	Acquisition items and discontinued operations	Impairment and other items	Restructure	Olympics	Total
Turnover	3,648	-	-	-	3,648	3,402	-	-	-	80	3,482
PBITA	201	-	(4)	(132)	65	202	-	19	(22)	(50)	149
Interest (incl. pensions)	(65)	-	-	-	(65)	(54)	-	-	-	-	(54)
Amortisation & acquisition expenses	-	(39)	-	(48)	(87)	-	(45)	-	-	-	(45)
PBT	136	(39)	(4)	(180)	(87)	148	(45)	19	(22)	(50)	50
Tax	(33)	10	1	3	(19)	(32)	12	(4)	3	10	(11)
Discontinued operations	-	(5)	-	(85)	(90)	-	(6)	-	-	-	(6)
PAT	103	(34)	(3)	(262)	(196)	116	(39)	15	(19)	(40)	33





Regional performance highlights

Africa

- 6% organic growth, partly impacted by major projects in Nigeria included in the prior year comparison which have now been completed
- Good PBITA progression to £20m (2012: £15m)
- Strong pipeline

Americas

- 5% organic growth impacted by reductions to US Border control contract and protest protection for US financial institutions. Good pipeline.
- PBITA maintained at £50m (2012: £50m) negative impact from increased workers compensation claims provisioning, contract transition incentives in 2012 and continued poor performance of Brazil technology business
- Agreed sale of Canadian cash solutions business for c£67m and Colombian secure archiving business for c£35m, both subject to customary closing conditions
- Sale of US Government Solutions and RSS businesses progressing to schedule



Regional performance highlights cont'd

Asia Middle East

- Organic growth of 16% and PBITA up by £5m to £50m
- Strong PBITA performances in Australia, New Zealand and the Middle East, partly
 offset by start up costs in China and completion of temporary work in Indonesia

Europe

- Negative organic growth of -2% and lower PBITA (-£6m) at £45m (2012: £51m) due to
 Dutch prison closures and weaker trading in a number of countries
- Restructuring programme in European region underway
- Recent contract wins encouraging



Regional performance highlights cont'd

UK & Ireland

- Organic growth of 5% and PBITA slightly lower (-£2m) at £60m (2012: £62m) due primarily to weaker performances in the UK and Ireland cash solutions businesses
- Strong pipeline in utility services
- Cash solutions UK restructuring underway
- Ireland good progress on restructuring plan
- UK Government contracts



Cash Flow and Net Debt

Six months ended 30 June 2013/12. 12 months ended 31 December 2012

£m	Jun-13	Jun-12	Dec-12
Net cash generated by operations	221*	212	372
Tax paid	(51)	(42)	(85)
Investment in business – capex	(80)	(60)	(137)
Investment in business – finance leases	(12)	(11)	(21)
Investment in business – acquisitions	(26)	2	(68)
Net interest	(71)	(65)	(111)
Total dividends	(84)	(86)	(139)
Other financing transactions	(11)	(6)	3
Translation adjustments	(34)	(11)	-
Net debt at the beginning of the period	(1,802)	(1,616)	(1,616)
Net debt at the end of the period	(1,950)	(1,683)	(1,802)

^{*}Includes £76m inflow from Olympics contract (2012: £12m) and £60m of deferred payments from 2012

Improved cash flow management a priority





Agenda

- Business review
- Interim results
- Capital structure and placing
- Outlook



Reasons for placing

- Balance sheet repair is required
 - Net debt/EBITDA of 3.2x at 30 June 2013
 - Risk of credit downgrade with associated c£25-30m per annum cost
- Self-help programme underway
 - Announced sale of two businesses in Canada and Colombia to raise c.£100m proceeds overall – 13.5x 2012 PBITA
 - US Gov't Solutions, RSS and other anticipated disposals to raise a further c£150m
 - Further portfolio management
 - Tighter working capital management
- Placing of 140.9 million new shares



Reasons for placing (cont'd)

Balance sheet repair provides flexibility to:

- Invest in the business to support organic growth, particularly in developing markets
- Business and product development resource
- Infill acquisitions
- Portfolio change from a position of strength
- Underpin competitive position when bidding for large projects

Providing the foundation to deliver sustainable, profitable growth



Strengthening balance sheet

- Net debt/EBITDA at 30th June: 3.2x
- Expect to announce disposals of c£100m
- Anticipated further disposals of c£150m (US/other)
- Equity placing of 140.9m shares
- Pro-forma Net debt/EBITDA : 2.2x
- Net debt/EBITDA objective: ≤2.5x



Agenda

- Business review
- Interim results
- Capital structure and placing
- Outlook



Outlook

- 5.4% organic growth reflects robust demand for the group's services and products
- Strong potential in the global sales pipeline of £4 billion
- Focus is to invest in
 - top line growth
 - operational capacity
 - begin restructuring a number of businesses
- Expect 2013 to be a year of consolidation
- Actions to deliver benefits during 2014 onwards



A&P





Appendix





Earnings per Share

Six months ended 30 June 2013

£m	2013	2012 at constant FX	2012 at actual FX
PBITA from continuing operations	201	202	200
Interest (including pensions)	(65)	(54)	(54)
PBTA from continuing operations	136	148	146
Tax	(33)	(32)	(32)
Tax rate	24%	22%	22%
Adjusted PAT	103	116	114
Non-controlling interests	(10)	(9)	(9)
Adjusted profit attributable to shareholders	93	107	105
Average number of shares (m)	1,403	1,404	1,404
EPS (p)	6.6	7.6	7.5
DPS (p)	3.42	3.42	3.42
	Lillian		_

Securing Your World

Balance Sheet

30 June 2013

	June	June	December
£m	2013	2012	2012
Goodwill and other intangibles	2,266	2,481	2,416
Tangible fixed assets	509	516	512
Other non-current assets	234	254	212
Current assets (excl cash)	1,855	1,720	1,817
Current liabilities (excl debt)	(1,298)	(1,381)	(1,322)
Non-current liabilities (excl debt)	(577)	(499)	(602)
Net debt	(1,950)	(1,683)	(1,802)
Net assets	1,039	1,408	1,231

Balance Sheet Review Analysis	£m
Current asset write-downs	17
Creditors, claims and provisions	40
Impairment of fixed assets	23
Impairment of receivables	52
Total included in PBITA	132
Impairment of goodwill	48
Total impact on results	180






Financing

- Unutilised committed facilities of £765m
- Average interest rate of 4.0% on gross borrowings in H1 2013
- Flexible access to long-term capital markets remains key to financing strategy

Available funding – maturity profile (£m) *







Pensions

Six months ended 30 June 2013

- Financial and actuarial assumptions updated as at June
- Calculations subject to short-term volatility
- Discount rate of 4.65% used for the UK
- Deficit decreased slightly to £404m from £436m at December 2012
- Additional cash contributions of £18m paid (no P&L implication)
- Cessation of future accruals in the UK
- Tri-annual evaluation in progress



Legal Disclaimer (1 of 3)

This presentation, which has been prepared by G4S PLC (the "Company"), is strictly confidential and is being provided to you solely for your information and comprises the written materials/slides for a presentation concerning a proposed placing of new ordinary shares of 25 pence each and in the capital of and by the Company (the "Placing"). Where used in this document, "Presentation" shall mean and include the slides that follow, the oral presentation of the slides by the Company's officers on behalf of the Company, any question and answer session that follows that oral presentation, hard copies of this Presentation and any materials distributed at, or in connection with, this Presentation. This Presentation and the information contained in it do not comprise a prospectus or constitute or form part of any offer to sell or issue, or any invitation or inducement or solicitation of any offer to purchase or subscribe for, any shares in the Company or any other securities in the United Kingdom, the United States or any other jurisdiction in which such offer, solicitation, inducement or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of that jurisdiction.

J.P. Morgan Securities plc (which conducts its UK investment banking business under the name J.P. Morgan Cazenove) ("JPM"), Citigroup Global Markets Limited ("Citi"), Barclays Bank PLC ("Barclays" and, together with JPM and Citi, the "Banks"), which are regulated in the United Kingdom by the Financial Conduct Authority, are acting for the Company in connection with the Placing and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to clients of the Banks or for providing advice in relation to the Placing. Persons receiving this Presentation will make all trading and investment decisions in reliance on their own judgement and not in reliance on the Banks or the Company. Any presentations, research or other information communicated or otherwise made available in this Presentation is incidental to the provision of services by the Banks to the Company and is not based on individual circumstances.

Neither this Presentation nor any part of it nor the fact of its distribution shall form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto, nor does it constitute a recommendation regarding the shares of the Company. Any decision to purchase securities of the Company must be made solely on the basis of the information gained from the recipients' own investigations and analysis of the Company. The information in the Presentation has been provided by the Company or obtained from publicly available sources, and has not been verified by the Company. None of the Company, its advisers, or any other party is under any duty to update or inform you of any changes to such information.

No reliance may be placed for any purposes whatsoever on the information contained in this Presentation or on its completeness and any such reliance for the purposes of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. No representation or warranty, express or implied, is given by or on behalf of the Company or the Banks or any of their respective parent or subsidiary undertakings, the subsidiary undertakings of any such parent undertakings or any of the directors, officers, employees or advisors or any other person as to the accuracy, fairness, sufficiency, verification or completeness of the information or opinions contained in this Presentation (or any part hereof) and, save in the case of fraud, neither the Company nor the Banks shall accept any liability for any loss, howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith. No person has been authorised to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorised. No statement in this Presentation is intended to be nor may be construed as a profit forecast.





Legal Disclaimer (2 of 3)

This Presentation and its contents are private and confidential and may not be reproduced, copied, redistributed or passed on, directly or indirectly, or disclosed by any recipient, to any other person or published, in whole or in part, for any purpose. This Presentation is therefore being communicated for information purposes only to a very limited number of persons and companies. This Presentation is only addressed to and is intended for distribution only to: (A) persons in member states of the European Economic Area (the "EEA") who are Qualified Investors within the meaning of Article 2(1)(e) of the EU Prospectus Directive (Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the relevant member state of the EEA) and includes any relevant implementing measure in each relevant member state of the EEA); and (B) in the United Kingdom, Qualified Investors who are persons who (i) have professional experience in matters relating to investments falling within Article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order; or (iii) are persons to whom it may otherwise be lawfully communicated, (all such persons together being referred to as "Relevant Persons"). If you are not a Relevant Person you should not have received this Presentation and please return the Presentation to an officer of the Company or to the Company's registered office as soon as possible and take no other action. The information contained in this Presentation is not to be viewed by, or distributed or passed on (directly or indirectly) to, and should not be acted upon by any other class of persons other than Relevant Persons.

This Presentation is not an offer of securities for sale in the United States. The securities discussed herein have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act"), as amended, and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No person in the United States who is not a qualified institutional buyer should participate in this Presentation and should immediately leave the room. By participating in this Presentation you are confirming to the Company that, if you are located in the United States, you are a qualified institutional buyer.

The securities discussed herein have not been and will not be registered under the applicable securities laws of Canada, Australia, South Africa, Jersey or Japan and, subject to certain exceptions, may not be offered or sold within Canada, Australia, South Africa, Jersey or Japan or to any national, resident or citizen of Canada, Australia, South Africa, Jersey or Japan. Neither this Presentation nor any copy of it may be taken or transmitted into Australia, Canada, Japan, Jersey or South Africa or to any securities analyst or person in any of those jurisdictions or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of Australian, Canadian, South African, Jersey or Japanese securities law. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions.

Certain information in this Presentation is based on management estimates. Such estimates have been made in good faith and represent the genuine belief of applicable members of management. Those management members believe that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete, and no representation or warranty (express or implied) is given that such estimates are so founded. The Company and the Banks do not undertake any obligation to correct or complete any estimate whether as a result of becoming aware of information (new or otherwise), future events or otherwise.





Legal Disclaimer (3 of 3)

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward looking statements can be identified by the use of a date in the future or forward-looking terminology, including, but not limited to, the terms "may", "believes", "estimates", "plans", "aims", "targets", "projects", "anticipates", "expects", "intends", "will", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements involve substantial risks and uncertainties and actual results and developments may differ materially from those expressed or implied by these statements and depend on a variety of factors. These statements are not historical facts and are regarding the Company's intentions, beliefs or current expectations. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements in this Presentation reflect the Company's view with respect to future events as at the date of this presentation and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity and the industry in which the Company operates. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No assurance can be given that the forward-looking statements in this presentation will be realised. The Company undertakes no obligation publicly to release the results of any revisions or updates to any forward-looking statements in this Presentation that may occur due to any change in its expectations or to reflect events or circumstances after the date of this presentation (except to the extent required by the Financial Conduct Authority, the London Stock Exchange or by applicable law, the Listing Rules or the Disclosure and T

Any information contained in this Presentation on the price at which shares or other securities in the Company have been bought or sold in the past, or on yield on such shares or other securities, should not be relied upon as a guide to future performance,

The information contained in this Presentation has yet to be announced or otherwise made public and as such constitutes inside information (within the meaning of section 118C of the Financial Services and Markets Act 2000 ("FSMA") about the Company or its securities) and non-public price sensitive information for the purposes of the Criminal Justice Act 1993 (the "CJA"). That information, which is given to you by the Company in the strictest confidence, has not been subject to public disclosure pursuant to the requirements of the Disclosure and Transparency Rules of the Financial Conduct Authority. Attendees of this Presentation are hereby notified that inappropriate behaviour in relation to inside information (including, but not limited to, dealing or attempting to deal in the shares or other financial instruments of the company on the basis of such information, any unauthorised disclosure such as disclosing it to another person otherwise than in the proper exercise of their employment, or otherwise misusing it) is market abuse under FSMA and may amount to the criminal offence of insider dealing under the CJA. Nothing in this Presentation constitutes investment advice and any recommendations that may be contained herein have not been based upon a consideration of the investment objectives, financial situation or particular needs of any specific recipient.

By attending the presentation to which this Presentation relates or by accepting this Presentation you will be taken to have represented, warranted and undertaken to the Company and the Banks that: (i) you are outside of the United States and you are a Relevant Person (as defined above); (ii) you have read and agree to be bound by and comply with the contents of this notice; (iii) you will keep the information in this Presentation and the Presentation and all information about the Placing confidential until such information has been made publicly available and take all reasonable steps to preserve such confidentiality; and (iv) following the Presentation, you will not at any time have any discussion, correspondence or contact concerning the information in this Presentation with any of the directors or employees of the Company or its subsidiaries nor with any of their suppliers or customers, or any governmental or regulatory body without the prior written consent of the Company.